참고문헌
- Andreasen PA (2007). PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets, 8, 1030-41. https://doi.org/10.2174/138945007781662346
- Bajou K, Masson V, Gerard RD, et al (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol, 152, 777-84. https://doi.org/10.1083/jcb.152.4.777
- Berger DH (2002). Plasmin/plasminogen system in colorectal cancer. World J Surg, 26, 767-71. https://doi.org/10.1007/s00268-002-4050-8
- Binder BR, Christ G, Gruber F, et al (2002). Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci, 17, 56-61.
- Bleeker FE, Molenaar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. J Neurooncol, 108, 11-27. https://doi.org/10.1007/s11060-011-0793-0
- Brandal S, Blake CM, Sullenger BA, et al (2011). Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Ther, 21, 373-81. https://doi.org/10.1089/nat.2011.0320
- Czekay RP, Wilkins-Port CE, Higgins SP, et al (2011). PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol, 2011, 562481.
- Dano K, Behrendt N, Hoyer-Hansen G, et al (2005). Plasminogen activation and cancer. Thromb Haemost, 93, 676-81.
- Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Asian Pac J Cancer Prev, 14, 7261-4. https://doi.org/10.7314/APJCP.2013.14.12.7261
- Eriksson P, Kallin B, van 't Hooft FM, et al (1995). Allelespecific increase in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A, 92, 1851-5. https://doi.org/10.1073/pnas.92.6.1851
- Gomes-Giacoia E, Miyake M, Goodison S, et al (2013). Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther, 12, 2697-708. https://doi.org/10.1158/1535-7163.MCT-13-0500
- Grubic N, Stegnar M, Peternel P, et al (1996). A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res, 84, 431-43. https://doi.org/10.1016/S0049-3848(96)00211-3
- Halamkova J, Kiss I, Pavlovsky Z, et al (2013). Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma, 60, 151-9.
- Isogai C, Laug WE, Shimada H, et al (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res, 61, 5587-94.
- Jiang Y, Uhrbom L (2012). On the origin of glioma. Ups J Med Sci, 117, 113-21. https://doi.org/10.3109/03009734.2012.658976
- McNamara MG, Sahebjam S, Mason WP (2013). Emerging biomarkers in glioblastoma. Cancers (Basel), 5, 1103-19. https://doi.org/10.3390/cancers5031103
- Ren F, Shi H, Zhang G, et al (2013). Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res, 32, 60. https://doi.org/10.1186/1756-9966-32-60
- Serao NV, Delfino KR, Southey BR, et al (2011). Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics, 4, 49. https://doi.org/10.1186/1755-8794-4-49
- Serce NB, Boesl A, Klaman I, et al (2012). Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer, 12, 597. https://doi.org/10.1186/1471-2407-12-597
- Sreekanthreddy P, Srinivasan H, Kumar DM, et al (2010). Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev, 19, 1409-22. https://doi.org/10.1158/1055-9965.EPI-09-1077
- Wang S, Cao Q, Wang X, et al (2013). PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis. PLoS One, 8, 56797. https://doi.org/10.1371/journal.pone.0056797
- Yasar Yildiz S, Kuru P, Toksoy Oner E, et al (2014). Functional stability of plasminogen activator inhibitor-1. Scientific World J, 2014, 858293.